Circulating Irisin in Relation to Insulin Resistance and the Metabolic Syndrome
Circulating Irisin in Relation to Insulin Resistance and the Metabolic Syndrome
复制标题
DOI：
10.1210/jc.2013-2373
复制
发表时间：
2013-12-01
影响因子：
5.8
通讯作者：
Mantzoros, Christos S.
中科院分区：
文献类型：
--
作者：
Park, Kyung Hee;Zaichenko, Lesya;Mantzoros, Christos S.
背景：鸢尾素，一种最近发现的激素，被认为可以调节小鼠的能量平衡和肥胖。鸢尾素水平是否与代谢综合征（MetS）风险、心脏代谢变量和心血管疾病（CVD）风险相关尚不清楚。目的：我们的目的是评估基线血清鸢尾素水平与MetS风险、心脏代谢变量和CVD风险之间的相关性。设计、设置和受试者：我们对新激素鸢尾素和已建立的脂肪因子脂联素的基线循环水平与MetS、心脏代谢变量、结果：MetS患者的基线鸢尾素水平显著高于无MetS患者。鸢尾素与脂联素呈负相关与体重指数呈正相关（r =-0.4，P < .001）（r = 0.22，P = .008），收缩压（r = 0.17，P = .04）和舒张压（r = 0.27，P = .001）血压、空腹血糖（r = 0.25，P = 0.002）、甘油三酯（r = 0.25，P = 0.003）和胰岛素抵抗的稳态模型评估（r = 0.33，P <0.001）。在调整了潜在的混杂因素（包括体重指数）后，鸢尾素水平最高的三分位数的受试者更有可能患有MetS。（比值比[OR] = 9.44，95%置信区间[CI] = 2.66-33.44），空腹血糖升高高甘油三酯（OR = 3.89，95% CI = 1.16-13.03）和低高密度脂蛋白胆固醇（OR = 3.30，95% CI = 1.18-9.20）。在校正混杂因素后，多元线性回归分析显示，鸢尾素与胰岛素抵抗的稳态模型评估和总体Fragrance风险特征独立相关。Adiponectin表现出预期的associations with outcomes.Conclusions：Irisin与MetS、心脏代谢变量和人类CVD风险增加相关，表明脂肪/肌肉组织分泌增加和/或Irisin代偿性增加，以克服这些受试者的潜在Irisin抵抗。
Context: Irisin, a recently identified hormone, has been proposed to regulate energy homeostasis and obesity in mice. Whether irisin levels are associated with risk of the metabolic syndrome (MetS), cardiometabolic variables, and cardiovascular disease (CVD) risk in humans remains unknown.Objective: Our objective was to assess the associations between baseline serum irisin levels and MetS, cardiometabolic variables, and CVD risk.Design, Setting, and Subjects: We conducted a comparative cross-sectional evaluation of baseline circulating levels of the novel hormone irisin and the established adipokine adiponectin with MetS, cardiometabolic variables, and CVD risk in a sample of 151 subjects.Results: Baseline irisin levels were significantly higher in subjects with MetS than in subjects without MetS. Irisin was associated negatively with adiponectin (r = -0.4, P < .001) and positively with body mass index (r = 0.22, P = .008), systolic (r = 0.17, P = .04) and diastolic (r = 0.27, P = .001) blood pressure, fasting glucose (r = 0.25, P = .002), triglycerides (r = 0.25, P = .003), and homeostasis model assessment for insulin resistance (r = 0.33, P < .001). After adjustment for potential confounders, including body mass index, subjects in the highest tertile of irisin levels were more likely to have MetS (odds ratio [OR] = 9.44, 95% confidence interval [CI] = 2.66-33.44), elevated fasting blood glucose (OR = 5.80, 95% CI = 1.72-19.60), high triglycerides (OR = 3.89, 95% CI = 1.16-13.03), and low high-density lipoprotein cholesterol (OR = 3.30, 95% CI = 1.18-9.20). Irisin was independently associated with homeostasis model assessment for insulin resistance and general Framingham risk profile in multiple linear regression analyses after adjustment for confounders. Adiponectin demonstrated the expected associations with outcomes.Conclusions: Irisin is associated with increased risk of MetS, cardiometabolic variables, and CVD in humans, indicating either increased secretion by adipose/muscle tissue and/or a compensatory increase of irisin to overcome an underlying irisin resistance in these subjects.